Stockreport

Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology

OREXO AB SP/ADR  (ORXOY) 
NASDAQ:AMEX Investor Relations: orexo.com/en/investors
PDF The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and [Read more]